The end of double digit growth

[Anonymous]

Novo Nordisk cuts annual sales guidance; Q1 profit rises 8 percent
(Ref: Bloomberg, The Wall Street Journal, CNBC, MarketWatch, Financial Times, Novo Nordisk, NASDAQ, The West Australian)
May 1st, 2014
By: Matthew Dennis
Tags: Top Story Victoza Novo Nordisk Corporate Affairs








Novo Nordisk said Thursday alongside its first-quarter financial results that sales this year are expected to grow between 7 percent and 10 percent in local currencies, down from an earlier forecast of 8 percent to 11 percent. The company partly attributed the decrease to "a challenging rebate and contract environment in the US," as well as generic competition to Prandin in the country.

CEO Lars Rebien Sørensen remarked "we are pleased to reiterate our expectations to operating profit growth for 2014 despite a challenging start of the year and a lower outlook for sales growth." Novo Nordisk expects operating profit growth in local currencies of around 10 percent.

For the first quarter, overall sales rose 2 percent year-over-year to 20.3 billion Danish kroner ($3.8 billion), with revenue from modern insulins increasing 4 percent to 9.4 billion kroner ($1.7 billion). In addition, sales of Victoza climbed 9 percent to 2.9 billion kroner ($540 million), although the figure missed analyst expectations of 3.1 billion kroner ($577 million). Meanwhile, net income in the three-month period was 8-percent higher at 6.5 billion kroner ($1.2 billion), beating analyst estimates of 6.3 billion kroner ($1.2 billion).

 

[Anonymous]

It's ashame when arrogance catches up with profits. Overpricing Victoza, losing ESI for the 2 most profitable drugs in your portfolio, hiring College kids to call on customers that no one wants to call on because they have either no volume or they are no-see. And who will pay the price for this shortfall? The sales people. Those who worked like dogs to get the greedy the 8%!

Here's a little clue, change upper management. They are not doing a good job.

 

[Anonymous]

It's ashame when arrogance catches up with profits. Overpricing Victoza, losing ESI for the 2 most profitable drugs in your portfolio, hiring College kids to call on customers that no one wants to call on because they have either no volume or they are no-see. And who will pay the price for this shortfall? The sales people. Those who worked like dogs to get the greedy the 8%!

Here's a little clue, change upper management. They are not doing a good job.

Ya lost mean when you stated "worked like dogs". NOBODY is overworked in our industry.

Enjoy the ride, but acknowledge that a job in pharma is a joke of a job. 5 mins of face-to-face time a day with targets who for the most part really do not want to even see you.

 

[Anonymous]

Ya lost mean when you stated "worked like dogs". NOBODY is overworked in our industry.

Enjoy the ride, but acknowledge that a job in pharma is a joke of a job. 5 mins of face-to-face time a day with targets who for the most part really do not want to even see you.

What you just said is one reason that ex-reps get dogged out when trying to leave the industry.

 

[Anonymous]

Ya lost mean when you stated "worked like dogs". NOBODY is overworked in our industry.

Enjoy the ride, but acknowledge that a job in pharma is a joke of a job. 5 mins of face-to-face time a day with targets who for the most part really do not want to even see you.

Sadly, a drug rep has more interaction in one day than actual action during an entire football game and I bet you still watch, play fantasy, and don't think the players jobs are worthless. You are a dumb ass doucher.

 

[Anonymous]

Ya lost mean when you stated "worked like dogs". NOBODY is overworked in our industry.

Enjoy the ride, but acknowledge that a job in pharma is a joke of a job. 5 mins of face-to-face time a day with targets who for the most part really do not want to even see you.

Quality vs quantity my friend!

 

[Anonymous]

Sadly, a drug rep has more interaction in one day than actual action during an entire football game and I bet you still watch, play fantasy, and don't think the players jobs are worthless. You are a dumb ass doucher.

And you are two to three years from finding out that "the doucher" post merely reflects the perception of our industry. Tick tock.

 

[Anonymous]

Sadly, a drug rep has more interaction in one day than actual action during an entire football game and I bet you still watch, play fantasy, and don't think the players jobs are worthless. You are a dumb ass doucher.

That's the best you could come up with?

 

[Anonymous]

Client Profile: Summary, 2014

A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple lobbying firms, each with a team of lobbyists, to press their case for them.

Novo Nordisk Pharmaceuticals
Total Lobbying Expenditures: $710,000

Subtotal for Parent Novo Nordisk Pharmaceuticals: $710,000 Novo Nordisk Pharmaceuticals Lobbying by Industry Industry Total
Pharmaceuticals/Health Products $710,000

Itemized Lobbying Expenses for Novo Nordisk Pharmaceuticals Firms Hired Total Reported by Filer Reported Contract Expenses (included in Total Reported by Filer)
Novo Nordisk Pharmaceuticals $710,000 -
Novo Nordisk Pharmaceuticals - $710,000
Alston & Bird - $60,000
DLA Piper - $30,000
Ryan, MacKinnon et al - $30,000
SLC Health Strategies - $27,000
Johnston Group - $10,000
Lawlor, Laura S - $0


Eli Lilly & Co
Total Lobbying Expenditures: $9,870,000

Itemized Lobbying Expenses for Eli Lilly & Co Firms Hired Total Reported by Filer Reported Contract Expenses (included in Total Reported by Filer)
Eli Lilly & Co $9,800,000 -
Eli Lilly & Co - $9,800,000
Monument Policy Group - $320,000
BGR Group - $290,000
Covington & Burling - $290,000
Nickles Group - $240,000
Foley Hoag LLP - $240,000
Heather Podesta & Partners - $240,000
McManus Group - $240,000
Ferguson Strategies - $120,000
OB-C Group - $80,000
Ricchetti Inc - $80,000
Rasky Baerlein Strategic Communications - $22,500
Ferrell, Kirk - $10,000
Panvini, Vincent A - $0
$2,172,500

Lobbying Expenses Reported by Subsidiary Lilly USA Firms Hired Total Reported by Filer Reported Contract Expenses (included in Total Reported by Filer)
FORGE Federal Affairs $40,000
FrogueClark LLC $30,000

.................ACA?

 

[Anonymous]

Client Profile: Summary, 2014

A special interest's lobbying activity may go up or down over time, depending on how much attention the federal government is giving their issues. Particularly active clients often retain multiple lobbying firms, each with a team of lobbyists, to press their case for them.

Novo Nordisk Pharmaceuticals
Total Lobbying Expenditures: $710,000

Subtotal for Parent Novo Nordisk Pharmaceuticals: $710,000 Novo Nordisk Pharmaceuticals Lobbying by Industry Industry Total
Pharmaceuticals/Health Products $710,000

Itemized Lobbying Expenses for Novo Nordisk Pharmaceuticals Firms Hired Total Reported by Filer Reported Contract Expenses (included in Total Reported by Filer)
Novo Nordisk Pharmaceuticals $710,000 -
Novo Nordisk Pharmaceuticals - $710,000
Alston & Bird - $60,000
DLA Piper - $30,000
Ryan, MacKinnon et al - $30,000
SLC Health Strategies - $27,000
Johnston Group - $10,000
Lawlor, Laura S - $0


Eli Lilly & Co
Total Lobbying Expenditures: $9,870,000

Itemized Lobbying Expenses for Eli Lilly & Co Firms Hired Total Reported by Filer Reported Contract Expenses (included in Total Reported by Filer)
Eli Lilly & Co $9,800,000 -
Eli Lilly & Co - $9,800,000
Monument Policy Group - $320,000
BGR Group - $290,000
Covington & Burling - $290,000
Nickles Group - $240,000
Foley Hoag LLP - $240,000
Heather Podesta & Partners - $240,000
McManus Group - $240,000
Ferguson Strategies - $120,000
OB-C Group - $80,000
Ricchetti Inc - $80,000
Rasky Baerlein Strategic Communications - $22,500
Ferrell, Kirk - $10,000
Panvini, Vincent A - $0
$2,172,500

Lobbying Expenses Reported by Subsidiary Lilly USA Firms Hired Total Reported by Filer Reported Contract Expenses (included in Total Reported by Filer)
FORGE Federal Affairs $40,000
FrogueClark LLC $30,000

.................ACA?

Does this mean along with express scripts Novo loses formulary on most state ACA exchanges too?

 

[Anonymous]

Anything mentioned at COE town hall meeting last week about the end of double digit growth?